SMC^® Human CTLA-4 High Sensitivity Immunoassay Kit

Cytotoxic T-lymphocyte protein 4 (CTLA-4) is an immune checkpoint receptor that plays a crucial role in regulating immune responses. By downregulating T cell activity, CTLA-4 helps prevent excessive immune reactions that could lead to tissue damage and autoimmune disease. However, in the context of cancer, CTLA-4 can be exploited by tumors to evade immune detection and destruction. This has led to the development of CTLA-4 inhibitors, which are used in cancer immunotherapy to enhance the immune system′s ability to target and eliminate tumor cells. CTLA-4 is a critical component of the immune system, balancing the need for effective immune responses against the risk of autoimmunity.

For ultrasensitive detection of CTLA-4 in human serum and plasma

Features:

• Robustness and Reproducibility: Lot-matched components ensure consistent assay performance across experiments, reducing variability and enhancing data reliability.
• Enhanced Detection Limits: Capable of detecting ultra-low analyte levels in the picogram and femtogram range, enabling the study of low-abundance biomarkers critical in early-stage research.
• Simplified Workflow Compatibility: Designed to align with standard assay workflows, including ELISA, minimizing the need for additional training or protocol adjustments.
• Certified Data Assurance: Each kit includes a Certificate of Analysis detailing validated assay characteristics, ensuring traceability and quality control for regulatory compliance.
• Wide Dynamic Range: Accurately quantifies analyte concentrations across a broad range, supporting both high and low abundance detection in complex samples.
• Automation Ready: Compatible with high-throughput systems, enabling seamless integration into automated workflows, reducing manual handling errors, and increasing efficiency.

Benefits:

• Understanding Immune Regulation: Ultrasensitive measurement of CTLA-4 allows researchers to explore immune modulation mechanisms, contributing to a deeper understanding of immune responses in various biological contexts.
• Modeling Disease Mechanisms: By measuring CTLA-4 levels, researchers can investigate its role in disease models, providing insights into the pathophysiology of conditions such as cancer and autoimmune diseases.
• Evaluating Therapeutic Strategies: In pre-clinical studies, monitoring CTLA-4 levels can help assess the effectiveness of novel immunotherapies or other treatments aimed at modulating immune responses.
• Biomarker Discovery: The ability to measure CTLA-4 sensitively may aid in identifying potential biomarkers for immune-related conditions, enhancing predictive models in research.
• Facilitating Drug Development: Understanding the dynamics of CTLA-4 in pre-clinical models can inform drug development processes, guiding the design of more effective therapies targeting immune checkpoints.

SMC is a registered trademark of Singulex